Morbidity burden and community-based palliative care are associated with rates of hospital use by people with schizophrenia in the last year of life: A population-based matched cohort study by Spilsbury, Katrina et al.
RESEARCH ARTICLE
Morbidity burden and community-based
palliative care are associated with rates of
hospital use by people with schizophrenia in
the last year of life: A population-based
matched cohort study
Katrina SpilsburyID1,2, Lorna Rosenwax3*, Kate Brameld1, Brian Kelly4, Glenn Arendts5,6
1 Centre for Population Health Research, Curtin University, Perth, Western Australia, Australia, 2 Institute for
Health Research, The University of Notre Dame Australia, Perth Western Australia, Australia, 3 School of
Occupational Therapy and Social Work, Curtin University, Perth, Western Australia, Australia, 4 Centre for
Brain and Mental Health Research and School of Medicine and Public Health, University of Newcastle,
Newcastle, New South Wales, Australia, 5 Centre for Clinical Research in Emergency Medicine, Harry
Perkins Institute of Medical Research, University of Western Australia, Perth, Western Australia, Australia,
6 Department of Emergency Medicine, Fiona Stanley Hospital, Perth, Western Australia, Australia
* L.Rosenwax@curtin.edu.au
Abstract
Objective
People with schizophrenia face an increased risk of premature death from chronic diseases
and injury. This study describes the trajectory of acute care health service use in the last
year of life for people with schizophrenia and how this varied with receipt of community-
based specialist palliative care and morbidity burden.
Method
A population-based retrospective matched cohort study of people who died from 01/01/
2009 to 31/12/2013 with and without schizophrenia in Western Australia. Hospital inpatient,
emergency department, death and community-based care data collections were linked at
the person level. Rates of emergency department presentations and hospital admissions
over the last year of life were estimated.
Results
Of the 63508 decedents, 1196 (1.9%) had a lifetime history of schizophrenia. After adjusting
for confounders and averaging over the last year of life there was no difference in the overall
rate of ED presentation between decedents with schizophrenia and the matched cohort (HR
1.09; 95%CI 0.99–1.19). However, amongst the subset of decedents with cancer, choking
or intentional self-harm recorded on their death certificate, those with schizophrenia pre-
sented to ED more often. Males with schizophrenia had the highest rates of emergency
department use in the last year of life. Rates of hospital admission for decedents with
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schizophrenia were on average half (HR 0.53, 95%CI 0.44–0.65) that of the matched cohort
although this varied by cause of death. Of all decedents with cancer, 27.5% of people with
schizophrenia accessed community-based specialist palliative care compared to 40.4% of
the matched cohort (p<0.001). Rates of hospital admissions for decedents with schizophre-
nia increased 50% (95% CI: 10%-110%) when enrolled in specialist palliative care.
Conclusion
In the last year of life, people with schizophrenia were less likely to be admitted to hospital
and access community-based speciality palliative care, but more likely to attend emergency
departments if male. Community-based specialist palliative care was associated with
increased rates of hospital admissions.
Introduction
The average life expectancy of people living with schizophrenia in developed countries is
around 20 years less than the general population [1, 2] although this varies by age of schizo-
phrenia onset and gender. [3] This has been mostly attributed to premature death from cardio-
vascular disease, respiratory diseases, cancers and injury [4]. Factors associated with these
excess early deaths include adverse side-effects of some antipsychotic medications [2]; under
diagnosis of metabolic syndrome [5]; reduced rates of cancer screening [6] resulting in more
advanced stages of cancer at diagnosis; high-risk lifestyle behaviours such as cigarette smoking
[4, 7], alcohol and drug use [4]; and high levels of other medical comorbidity. [8] A review of
cancer care in people with schizophrenia reported they experienced longer delays from diag-
nosis to treatment, were less likely to undergo surgery but had greater 30 day mortality post-
surgery and received fewer chemotherapy and radiotherapy sessions. [9]
The episodic positive symptoms of schizophrenia such as delusions, thought disorder and
hallucinations and the negative symptoms of apathy, social withdrawal, reduced self-care and
cognitive dysfunction may act as barriers to accessing appropriate health care. [10, 11] A Cana-
dian study reported that in the last six months of life, people with schizophrenia had more vis-
its to general practitioners and psychiatrists but fewer visits to medical specialists, 27% less
hospitalisations and were less likely to receive palliative care compared to a matched cohort.
[12] A study from the United States reports that having any pre-existing psychiatric illness was
associated with less acute care hospitalisations and intensive care but higher rates of ED pre-
sentations in the last 30 days of life and a greater likelihood of dying in a nursing home. [13] In
contrast, a study of end-of-life care for mostly male US war veterans dying with cancer found
those with schizophrenia received comparable care with similar proportions of patients who
underwent surgical treatment for cancer, enrolled in hospice care and had advance directives
and resuscitation orders in place, although a lower proportion of veterans with schizophrenia
initiated chemotherapy. [14]
Community-based specialist palliative care delivered in the home or place of residence in
the last year of life is associated with reduced presentations to ED [15, 16], reduced admissions
to hospital [17, 18], shorter lengths of hospital stays [19, 20] and reduced hospital costs. [21]
While most studies have focused on people dying with cancer, the evidence supporting the
benefit of specialist palliative care in the setting of life-limiting non-cancer conditions is grow-
ing. [22, 23]
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The aim of this study was to describe the trajectory of acute care health service use in the
last year of life for people with schizophrenia and how this varied with morbidity burden,
cause of death and access to community-based specialist palliative and non-palliative care. We
hypothesised that people with schizophrenia would show low rates of community-based spe-
cialist palliative care in the last year of life, but that barriers to accessing acute care health ser-
vices would be reduced in those who did.
Methods
This was a population-based retrospective matched cohort study of acute health care service and
community-based health care service use over the last year of life in people who died from 1 Janu-
ary 2009 to 31 December 2013 with or without a history of schizophrenia and aged 20 years and
older in Western Australia (WA). Decedents with a lifetime history of schizophrenia, schizophre-
nia-like psychosis or schizoaffective disorders were eligible for inclusion and are referred to collec-
tively as the schizophrenia cohort. Decedents in the schizophrenia cohort were identified from
coded administrative data by searching all death registrations in WA from 2009 to 2013 and per-
son-linked hospital admissions (1979 to 2013), emergency department (ED) presentations (2005
to 2013) and mental health registrations (1970 to 2013) using International Classification of Dis-
eases (ICD) Version 9 [24] code 295 and ICD-10-AM codes F20, F21, F231, F232 and F25. [25]
Data linkage and de-identified data extraction from the WA Data Linkage System was performed
by the Data Linkage Branch at the WA Department of Health. In the absence of a unique personal
identifier in Australia, the WA Data Linkage System uses probabilistic matching based on name
and other identifiers. [26] Ethical approval to conduct this retrospective study on anonymized
data with a waiver of the requirement to obtain consent was provided by the Human Research
Ethics Committees at the WA Department of Health and Curtin University.
Matching for population-based comparison cohort
Coarsened exact matching (CEM) was used to identify a matched comparison cohort of dece-
dents without a history of schizophrenia. Matching was performed to create a similar balance
in age groups, sex, partner status, indigenous status, residential location, relative social disad-
vantage and country of birth in both the schizophrenia and comparison cohorts. [27] Observa-
tions were weighted according to the size of the matching strata with unmatched population
controls excluded. Matching and statistical analyses were adjusted for indigenous status, but
we do report separately for this population subgroup.
Causes of death
The Australian Bureau of Statistics uses ICD-10 to conduct multiple cause coding of all death
certificates in Australia. The underlying cause of death is defined as “the disease or injury
which initiated the train of morbid events leading directly to death. . .”, while other morbid
conditions are classified as intermediate/intervening causes of death or contributory causes.
[28] For the purposes of analysis we created cause of death groups from the reported leading
causes of death overall in Australia [29]; most common causes of death in the cohort of dece-
dents with schizophrenia; and less common causes of death that were over represented in the
schizophrenia cohort compared to the matched cohort (S1 Table).
Social and demographic variables
Marital status was classified as partnered (married or de-facto) or not/unknown at time of hos-
pital admission, ED presentation and at time of death. Each decedent’s address was geocoded
End of life health service use in people with schizophrenia
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and used to assign accessibility categories based on the Australian ARIA+ index that takes into
account road distance measurements to the nearest Service Centres and population size. [30]
Socioeconomic status was estimated using quintiles of the Index of Relative Disadvantage
(IRSD) which estimates the average disadvantage of small geographic areas. [31] Manual geo-
coding was also used to identify the type of residence at ED presentation, hospital admission
and at death for decedents with schizophrenia and were classified as independent living (e.g.
private residence); residential aged care facility (RACF); other care facility; no fixed address
(e.g. homeless); and unknown/not stated.
Morbidity burden. Morbidity was defined as the presence of one or more of the 31 Elix-
hauser [32] conditions recorded in the primary or other 21 diagnostic fields during in-patient
hospital stays over the last five years of life. [33] Morbidity burden was recorded as a temporal
variable over the last year of life. For example, a decedent who had first mention of cancer on
hospital admission at six months before death would have been recorded as having zero mor-
bidity burden for the first six months of the last year of life before increasing to one after the
cancer-related admission. We included psychoses in the calculation of total morbidity burden
because this allowed us to differentiate health service use in decedents with schizophrenia
before and after first mention of hospital admission for psychosis.
Outcome measure: Emergency department presentations
Emergency department (ED) presentations were assigned daily per person and only the first
ED visit per day was included in the time-to-event analysis. The ED presentations as part of
inpatient hospital transfers were excluded. Available ED data included the triage category, hos-
pital admission status, specific diagnosis and presenting symptom. Coded presenting symptom
data and ICD-10 coded diagnosis data were only available for metropolitan based hospitals
(approximately 70% of ED presentations). Comparative analyses involving coded ED present-
ing symptom and diagnosis data excluded non-coded ED presentations from the estimation
process.
Outcome measure: Hospital admissions
Hospital data were provided at the patient level in episodes of care. Multiple episodes of care
were brought together into a single hospital admission when they included a statistical dis-
charge (e.g. change of hospital care type but still in hospital) or transfer to another hospital.
The principal diagnosis for the hospital admission was taken from the earliest episode of care
when multiple episodes of care were present.
Community-based care
The Western Australian Home and Community Care (HACC) Program is a Commonwealth
and State Government funded program that provides support services to frail older people and
younger people with disabilities and their carers for a nominal fee. Services provided included
basic nursing care (e.g. wound dressings), personal care (e.g. showering), domestic assistance
(e.g. shopping, house cleaning), assistance with maintaining social support, client care coordi-
nation, allied health (e.g. podiatry), group activity centres, transport and meals. The types of
services accessed by decedents in the last year of life was available, but patterns of service use
over the last year of life could not be described due to lack of reliable date information.
Silver Chain WA is the main provider of community-based specialist palliative care in WA,
although the most comprehensive service is restricted to major metropolitan areas. A team of
palliative care clinicians and nurses, allied health professionals and volunteers provide home
nursing care, counselling, respite options, practical support and links to other services with the
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aim of enabling people with life-limiting illness to remain at home. A palliative nurse consul-
tancy service is available to residential care facilities where client care is managed by registered
nurses. A palliative care rural telephone advisory service provides specialist advice to local
rural service providers 24 hours per day. Study data included enrolment and discharge dates
into each Silver Chain service and the number and length of time of home visits. A client may
have had multiple periods of enrolment if their condition was of a relapsing and remitting
nature. Life-limiting conditions considered amenable to palliative care for this study were can-
cers, heart failure, renal failure, liver failure, chronic obstructive pulmonary disorder, motor
neurone disease, Parkinson’s disease and Alzheimer’s disease as described previously. [34]
Statistical analysis
Strata-weighted chi-square tests were used to assess equality of proportions. Differences
between means were assessed with design-adjusted Wald tests. Multiple failure time-to-event
analyses were performed to investigate the association of schizophrenia with acute care health
service use in the last year of life. The multiple failure outcome events of interest were ED pre-
sentations and hospital admission any time in the one-year follow-up period. As cause of
death is strongly associated with health service use, separate time-to-event analyses of the asso-
ciation of schizophrenia with health service use were performed for each cause of death. Dece-
dents were excluded from the risk pool during periods of hospital stays.
A weighted kernel-density estimate of the hazard was used to graph unadjusted rates of ED
presentations and hospital admissions over the last year of life. Time-to-event analyses were
performed using flexible parametric Royston-Parmar models. [35] Variables that demon-
strated temporal changes were treated as time-varying covariates including state of hospitalisa-
tion, number of comorbid conditions, partner status, residence in areas of relative
disadvantage and level of accessibility to services. Standard errors were adjusted using the clus-
tered sandwich estimator to account for correlated time between failure events. Matching
strata weights were applied in all estimation procedures involving the matched comparison
cohort. Variables used in the matching process were also included in regression analyses for
full adjustment. The Sidak correction for multiple testing for each cause of death, assuming an
alpha of 0.05 and 30 simultaneous comparisons, estimated a p-value of<0.0017 would demon-
strate evidence of an association. Stata Statistical Software: Release 14 (Stata Corp, College Sta-
tion, TX) was used.
Results
Of the 63508 deaths in WA, 1196 (1.9%) of decedents had a lifetime history of schizophrenia.
Decedents with schizophrenia were younger, lived in urban areas of more socioeconomic dis-
advantage, were more likely born in Australia and to have no partner at time of death com-
pared to the general population of decedents (Table 1). A matched comparison cohort of
39265 decedents without a history of schizophrenia matched into 511 strata by age at death,
sex, partner status at earliest record, indigenous status, residence in a major metropolitan area
or not, socioeconomic disadvantage and country of birth was identified, each with a weighting
relative to strata size. Two female decedents with schizophrenia could not be matched and
were excluded from comparative analysis.
Amongst decedents with schizophrenia, the demographic profile varied by sex. The average
age at first schizophrenia record was 28.2 (standard deviation (SD) 8.1) years for males and
30.1 (SD 8.4) years for females (p = 0.099). A greater proportion of female decedents with
schizophrenia (n = 265, 46.7%) were living in a residential aged care facility at time of death
compared to males (n = 136, 22.4%), whereas a greater proportion of males were homeless or
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without a fixed address at time of death (n = 10, 1.6%) compared to females (<5, 0.2%). More
male decedents with schizophrenia (n = 433, 70%) were born in Australia compared to females
(n = 350, 61%). A greater proportion of female decedents with schizophrenia lived in urban
areas (n = 457; 80% versus n = 447; 72%) while a greater proportion of males with schizophre-
nia died aged less than 30 years (n = 43; 7% versus n = 7; 1%).
Causes of death
The most frequent principal causes of death in the schizophrenia cohort were cancers, ischae-
mic heart disease, intentional self-harm, chronic lower respiratory disease, dementias and acci-
dental poisoning (Table 2). One third of decedents with schizophrenia had cancer recorded on
Table 1. Socio-demographic characteristics at time of death for decedents with schizophrenia compared to all other decedents who died over the same time five-
year time period 2009–2013.
All other
decedents
(n = 62312)
Decedents with
schizophrenia
(n = 1196)
Chi-squared
test
p-value
N % N %
Age at death (years)
20–29 972 1.6 51 4.3
30–39 1352 2.2 88 7.4
40–49 2508 4.0 130 10.9
50–59 4728 7.6 170 14.2 <0.001
60–69 7790 12.5 212 17.7
70–79 12550 20.1 228 19.1
80–89 20924 33.6 241 20.2
90+ 11488 18.4 76 6.4
Sex
Male 32799 52.6 622 52.0 0.666
Female 29513 47.4 574 48.0
Index of relative social disadvantage
Most disadvantaged 16437 26.4 375 31.4 <0.001
More disadvantaged 13209 21.2 275 23.0
Average disadvantage 10807 17.3 218 18.2
Less disadvantaged 9578 15.4 148 12.4
Least disadvantaged 8342 13.4 111 9.3
Unknown 3939 6.3 69 5.8
Partner status
Not partnered 30498 48.9 981 82.0 <0.001
Partnered 31814 51.1 215 18.0
Accessibility index
Major cities 45430 72.9 919 76.8 <0.001
Inner regional 5297 8.5 58 4.8
Outer regional 5154 8.3 91 7.6
Remote 1723 2.8 44 3.7
Very remote 820 1.3 16 1.3
Unknown 3888 6.2 68 5.7
Born in Australia
No 26205 42.1 412 34.4 <0.001
Yes 36107 57.9 784 65.6
https://doi.org/10.1371/journal.pone.0208220.t001
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Table 2. The leading causes of death for decedents with schizophrenia (n = 1194) compared against decedents in the matched control cohort (n = 39,265) by under-
lying cause or any mention of the cause on the death certificate.
Leading causes of death Underlying cause of death1 Any mention on death certificate2
SCZ
cohort
Matched
cohort†
SCZ
cohort
Matched
cohort†
N % N % p N % N % p
Infectious diseases
Bacterial sepsis 17 1.4 347 0.9 0.018 69 5.8 2305 5.9 0.772
Neoplasms
All cancers 199 16.7 11885 30.3 <0.001 218 18.3 13474 34.3 <0.001
Lung cancer 46 3.9 2423 6.2 0.001 47 3.9 2586 6.6 <0.001
Breast cancer 23 1.9 708 1.8 0.284 28 2.3 990 2.5 0.222
Of ill-defined sites 18 1.5 622 1.6 0.732 54 4.5 3028 7.7 <0.001
Colorectal cancer 17 1.4 1032 2.6 0.010 19 1.6 1222 3.1 0.005
Blood & lymph cancers 16 1.3 1076 2.7 0.010 20 1.7 1382 3.5 0.007
Endocrine system
Diabetes 39 3.3 1206 3.1 0.465 145 12.1 4221 10.8 0.003
Mental/behavioural
Dementias 65 5.4 2976 7.6 0.046 154 12.9 6160 15.7 <0.001
Schizophrenia 22 1.8 0 0.0 <0.001 208 17.4 0 0.0 <0.001
Due to use of alcohol 6 0.5 59 0.2 0.127 50 4.2 604 1.5 0.421
Due to use of drugs 6 0.5 30 0.1 0.276 39 3.3 192 0.5 0.002
Bipolar affective disorders 5 0.4 <5 0.0 <0.001 43 3.6 57 0.1 <0.001
Depressive episodes <5 0.1 16 0.0 0.323 52 4.4 786 2.0 <0.001
Nervous system
Parkinson’s disease 13 1.1 307 0.8 0.005 26 2.2 693 1.8 <0.001
Epilepsy 9 0.8 65 0.2 0.035 23 1.9 281 0.7 0.043
Circulatory system
Ischaemic heart disease 174 14.6 5836 14.9 0.205 277 23.2 10402 26.5 0.406
Cerebrovascular disease 53 4.4 2645 6.7 0.702 110 9.2 5298 13.5 0.665
Heart failure 25 2.1 760 1.9 0.013 138 11.6 5656 14.4 0.041
Hypertensive disease 12 1.0 470 1.2 0.412 119 10.0 5613 14.3 0.748
Respiratory system
CLRD 70 5.9 1561 4.0 <0.001 137 11.5 3706 9.4 <0.001
Influenza, pneumonia 24 2.0 632 1.6 0.093 174 14.6 4855 12.4 <0.001
Pneumonitis due to solids/liquids 13 1.1 232 0.6 <0.001 61 5.1 1539 3.9 <0.001
Asthma 9 0.8 100 0.3 0.052 17 1.4 380 1.0 0.239
Digestive system
Cirrhosis/liver disease 15 1.3 446 1.1 0.038 33 2.8 1240 3.2 <0.001
Intestinal obstruction 9 0.8 154 0.4 0.001 16 1.3 535 1.4 0.768
Genitourinary system
Renal diseases/dialysis 16 1.3 701 1.8 0.970 90 7.5 4820 12.3 0.026
Signs and symptoms
Ill-defined/ unknown 21 1.8 205 0.5 0.010 33 2.8 306 0.8 <0.001
Injury and poisoning
Intentional self-harm 109 9.1 734 1.9 <0.001 109 9.1 716 1.8 <0.001
Accidental poisoning3 64 5.4 353 0.9 <0.001 96 8.0 661 1.7 <0.001
Accidental falls 16 1.3 655 1.7 0.866 22 1.8 892 2.3 0.695
Choking on food/liquid4 8 0.7 12 0.0 <0.001 9 0.8 24 0.1 <0.001
(Continued)
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their death certificate compared to more than half of all decedents in the matched cohorts. The
exception was for breast cancer, where no difference between the cohorts was noted. The pro-
portion of deaths in the schizophrenia cohort from diseases of the circulatory system were the
same as that for the matched cohort. Amongst decedents with schizophrenia, a greater propor-
tion of males had an underlying cause of death from intentional self-harm (n = 86, 14%) or
accidental poisoning (n = 49, 8%) compared to females (n = 23, 4% and n = 15, 3% respec-
tively, p<0.001).
The average total morbidity burden at the beginning of the last year of life was similar in
the schizophrenia cohort and matched controls but the type of conditions varied (Table 3).
Decedents with a lifetime history of schizophrenia had a higher proportion of uncomplicated
diabetes, chronic pulmonary disease, neurological disorders, depression, hypothyroidism, obe-
sity, alcohol and drug abuse and psychoses recorded in the five years prior to the last year of
life relative to the matched cohort. The matched cohort had a significantly higher proportion
of decedents with a history of cancer, circulatory disorders and liver disease at the start of the
last year of life.
ED presentations over the last year of life
ED presentations were more frequent for male decedents with schizophrenia compared to
matched male controls (Table 4). Decedents with a history of schizophrenia tended towards
less urgent ED presentations which were more likely to occur for social or behavioural symp-
toms or related to alcohol use relative to the matched comparison cohorts, with the difference
more marked in males. A greater proportion of decedents with schizophrenia were trans-
ported to ED by police or correctional services compared to the matched cohort.
The rate of ED presentations was not constant over the last five years of life (Fig 1A). The
unadjusted rate of ED visits over the last year of life was consistently higher in the schizophre-
nia cohort compared to matched cohort until the last two months of life when the rate of ED
presentation of the matched cohort increased rapidly. When stratified by sex, most of the
increased rate of ED presentations in schizophrenia appear to be driven by males.
After adjusting for confounders and averaging over the last year of life there was no differ-
ence in the rates of ED presentation between decedents with schizophrenia and the matched
cohort (HR 1.09; 95%CI 0.99–1.19). However, testing for interaction terms indicated that the
degree of association was strongly modified by gender and by the number of comorbid condi-
tions (Fig 1B). Amongst male decedents with no comorbid condition, the rate of ED use was
greatest in males with schizophrenia, whereas amongst female decedents with no comorbidity,
Table 2. (Continued)
Leading causes of death Underlying cause of death1 Any mention on death certificate2
SCZ
cohort
Matched
cohort†
SCZ
cohort
Matched
cohort†
N % N % p N % N % p
All other causes 154 12.9 6303 16.1
1The disease or injury that initiated the train of morbid events leading to death.
2The number and proportion of decedents with this cause recorded anywhere on the death certificate (either underlying, antecedent or contributory cause of death).
3Includes poisoning by non-opioid analgesics, antipyretics, antirheumatics, narcotics, psychodysleptics, antiepileptic, sedative-hypnotic, antiparkinsonism or
psychotropic drugs.
4 Inhalation and ingestion of food causing obstruction of respiratory tract.
†Strata weights applied and p-values estimated from design adjusted chi-square tests. SCH, schizophrenia; CLRD, chronic lower respiratory disease
https://doi.org/10.1371/journal.pone.0208220.t002
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Table 3. The number of decedents with specific morbid conditions at one year before death in the schizophrenia
and matched cohorts estimated from 5-year look back of hospital records.
Morbidity burden
at one year before death
Schizophrenia
cohort
Matched
cohort†
N Col % N Col % p
Elixhauser comorbid conditions
Psychoses� 294 24.6 77 0.2 <0.001
Hypertension, Uncomplicated 140 11.7 5410 13.8 0.045
Congestive Heart Failure 115 9.6 3689 9.4 0.786
Diabetes, Uncomplicated� 109 9.1 2521 6.4 <0.001
Chronic Pulmonary Disease� 105 8.8 2681 6.8 0.009
Alcohol Abuse� 97 8.1 2493 6.4 0.019
Depression� 82 6.9 1299 3.3 <0.001
Other Neurological Disorders� 80 6.7 1619 4.1 <0.001
Fluid and Electrolyte Disorders 75 6.3 2621 6.7 0.599
Drug Abuse� 68 5.7 823 2.1 <0.001
Cardiac Arrhythmias 67 5.6 3220 8.2 0.001
Renal Failure 64 5.4 2796 7.1 0.021
Solid Tumour Without Metastasis 59 4.9 5245 13.4 <0.001
Metastatic Cancer 56 4.7 4346 11.1 <0.001
Diabetes, Complicated 46 3.9 1695 4.3 0.446
Weight Loss 34 2.8 861 2.2 0.136
Liver Disease 33 2.8 1785 4.5 0.004
Obesity� 32 2.7 655 1.7 0.011
Peripheral Vascular Disorders 25 2.1 1459 3.7 0.004
Hypothyroidism� 24 2.0 359 0.9 <0.001
Valvular Disease 16 1.3 831 2.1 0.067
Deficiency Anaemia 16 1.3 771 2.0 0.129
Paralysis 15 1.3 487 1.2 0.964
Coagulopathy 15 1.3 804 2.0 0.060
Pulmonary Circulation Disorders 14 1.2 1003 2.6 0.003
Hypertension, Complicated 11 0.9 276 0.7 0.387
Rheumatoid Arthritis/Collagen Vascular 6 0.5 366 0.9 0.129
Lymphoma <5 0.3 479 1.2 0.006
Blood Loss Anaemia <5 0.3 182 0.5 0.525
Peptic Ulcer Disease Excluding Bleeding <5 0.2 221 0.6 0.072
AIDS/HIV <5 0.1 62 0.2 0.533
At beginning of last year
Decedents with no comorbidity (n, %) 450 37.7 16054 40.9 0.119
No. conditions per decedent (mean, se) 1.4 0.05 1.3 0.01 0.013
At time of death
Decedents with no comorbidity (n, %) 169 14.2 7084 18.0 0.002
No. conditions per decedent (mean, se) 3.7 0.1 3.5 0.02 0.036
No., number of conditions; Col, column �Overrepresented in decedents with schizophrenia
†Strata weights applied and p-values estimated from design adjusted chi-square tests. Values are those estimated as if
the comparison cohort had the same age, sex, socioeconomic, partner, indigenous and country of birth structure as
the schizophrenia cohort.
https://doi.org/10.1371/journal.pone.0208220.t003
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Table 4. Summary characteristics of ED presentations and hospital stays in the last year of life for decedents in the schizophrenia and matched comparison cohort
stratified by sex.
Female decedents Male decedents
In the last year of life Schizophrenia
n = 572
Matched†
n = 20591
p Schizophrenia
n = 622
Matched†
n = 18672
p
ED presentations
Total cohort ED visits (n, row %) 1338 3.2 40708 96.8 2020 4.1 47293 95.9
Decedents presented (n, col%)
No 154 26.9 4493 23.9 0.114 170 27.3 5630 27.5 0.929
Yes 418 73.1 14305 76.1 452 72.7 14838 72.5
ED visits/decedent (mean, se) 2.3 0.1 2.2 0.1 0.249 3.3 0.4 2.3 0.5 0.016
Transport to ED by police (n, col%) 38 2.8 128 0.3 <0.001 75 3.7 837 1.8 <0.001
Triage category (n, col%)
Resuscitation 72 5.4 1982 4.8 0.183 89 4.4 3417 7.2 <0.001
Emergency 243 18.2 8077 19.8 348 17.2 9081 19.2
Urgent 543 40.6 17374 42.7 712 35.2 18870 39.9
Semi-urgent 411 30.7 11409 28.0 682 33.8 12325 26.1
Non-urgent 67 5.0 1805 4.4 183 9.1 3513 7.4
Presenting symptoms‡(n, col%)
Pain 210 20.0 7509 24.5 <0.001 296 20.3 7295 22.1 <0.001
Respiratory 185 17.6 4944 16.1 223 15.3 4744 14.4
Neurological 175 16.7 4932 16.1 195 13.4 4556 13.8
Injury 88 8.4 2481 8.1 103 7.1 2776 8.4
Social /behavioural 92 8.8 765 2.5 171 11.8 1230 3.7
Drug/alcohol related 13 1.2 327 1.1 181 12.4 1236 3.8
Hospital admissions
Total cohort admissions (n,row %) 1828 1.7 108326 98.3 2162 1.9 113462 98.1
Decedents admitted (n, col%)
No 157 27.4 3556 18.9 <0.001 175 28.1 6094 29.8 0.410
Yes 415 72.6 15242 81.1 447 71.9 14373 70.2
Admissions/decedent (mean, se) 3.2 0.4 5.8 0.2 <0.001 3.5 0.5 5.5 0.2 <0.001
Length of stay (mean, se) 7.7 0.4 5.1 0.1 <0.001 8.1 0.5 4.5 0.1 <0.001
Hospital stay care type (n, col%)
Acute care 1727 94.5 104472 96.4 <0.001 2093 96.8 110299 97.2 <0.001
Rehabilitation 6 0.3 280 0.3 3 0.1 214 0.2
Palliation 32 1.8 3122 2.9 41 1.9 2625 2.3
Psychogeriatric care 41 2.2 237 0.2 16 0.7 173 0.2
Maintenance 22 1.2 188 0.2 8 0.4 137 0.1
Admissions (n, col %) involving
Psychiatric care€ 132 7.2 551 0.5 <0.001 204 9.4 725 0.6 <0.001
Emergency admission¥ 995 54.4 34410 31.8 <0.001 1221 56.5 34751 30.6 <0.001
Stay in ICU 34 1.9 1600 1.5 0.193 64 3.0 2273 2.0 0.002
Ventilator support 25 1.4 905 0.8 0.018 42 1.9 1651 1.5 0.074
ED, emergency department; se, standard error; col, column; n, number; ICU, intensive care unit.
† Coarsened exact matching strata weights applied and p-values corrected to account for study design. Values are those estimated as if the comparison cohort had the
same age, sex, socioeconomic, partner, indigenous and country of birth structure as the schizophrenia cohort.
‡ Estimated from the 70% of ED presentations coded with symptom and diagnostic information.
¥ Includes admissions via the ED and direct admissions to speciality care areas such as intensive care and burns units or via the ED of another hospital.
Hospital stay involved one or more days within a designated psychiatric unit.
https://doi.org/10.1371/journal.pone.0208220.t004
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the rate of ED use was highest amongst females in the matched cohort. With two comorbid
conditions, the rate of ED presentations was lower for both female and male decedents with
schizophrenia compared to their gender matched cohorts and by four comorbid conditions,
there was no significant differences between the sexes or cohort in rate of ED presentations.
We investigated whether the rates of ED presentation between decedents in the schizophre-
nia and matched cohorts varied by causes of death (Table 5). Of all decedents who had cancer,
Fig 1. The average yearly (hazard) rate of ED presentations per decedent over the last year of life for the
schizophrenia and matched cohorts and stratified by sex, estimated from A) an unadjusted kernel-weighted
estimator of the hazard and B) an adjusted flexible parametric proportional hazards model. Values in B) predicted
for Australian born non-Indigenous decedents living in a metropolitan area of average disadvantage without a partner,
and aged 50 years or older at death. Sex and comorbidity were entered as interaction terms.
https://doi.org/10.1371/journal.pone.0208220.g001
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Table 5. Adjusted relative rates of ED presentations and hospital admission by decedents in the schizophrenia cohort compared to decedents in the matched cohort
from multiple regression models for each cause of death listed anywhere on the death certificate.
Cause of death
decedent subsets¥
ED presentations† Hospital admission†
HR 95%CI p HR 95%CI p
Bacterial sepsis 1.3 0.8–2.0 0.255 0.3 0.2–0.4 <0.001
Neoplasms
All cancers combined 1.2 1.1–1.4 0.005 0.6 0.5–0.8 <0.001
Lung cancer 1.5 1.2–1.9 0.002 0.6 0.5–0.8 <0.001
Breast cancer 1.3 0.9–2.0 0.132 0.9 0.7–1.3 0.680
Colorectal cancer 0.8 0.4–1.7 0.590 0.5 0.3–1.0 0.037
Blood & lymph 0.8 0.5–1.3 0.432 0.3 0.2–0.5 <0.001
Ill-defined sites 1.4 1.1–1.8 0.018 0.6 0.5–0.8 0.001
Endocrine system
Diabetes 1.0 0.8–1.2 0.767 0.5 0.3–0.9 0.014
Mental/behavioural
Dementias 0.8 0.7–1.0 0.089 0.5 0.3–0.7 <0.001
Due to use of alcohol 0.8 0.5–1.1 0.160 0.3 0.2–0.5 <0.001
Due to use of drugs 1.3 0.8–2.2 0.264 0.5 0.3–0.9 0.017
Schizophrenia NE NE
Bipolar affective disorders 0.9 0.6–1.3 0.479 0.5 0.2–1.1 0.082
Depressive episodes 0.7 0.5–1.1 0.093 0.5 0.3–0.8 0.007
Nervous system
Epilepsy 1.0 0.5–1.7 0.874 0.7 0.4–1.3 0.273
Parkinson’s disease 0.8 0.5–1.3 0.394 0.4 0.1–1.2 0.113
Circulatory system
Ischaemic heart disease 1.1 1.0–1.4 0.107 0.4 0.3–0.7 <0.001
Heart failure 1.0 0.8–1.3 0.778 0.6 0.5–0.8 <0.001
Cerebrovascular disease 1.0 0.8–1.2 0.870 0.3 0.2–0.6 <0.001
Hypertensive disease 1.1 0.8–1.4 0.667 0.6 0.3–1.1 0.122
Respiratory system
Influenza, pneumonia 0.8 0.7–1.0 0.028 0.5 0.4–0.6 <0.001
Chronic lower respiratory disease 1.1 0.8–1.3 0.591 0.7 0.4–1.2 0.181
Asthma 1.1 0.5–2.5 0.795 0.2 0.0–1.2 0.076
Pneumonitis due to solids/liquids 0.9 0.7–1.2 0.558 0.6 0.5–0.8 <0.001
Digestive system
Intestinal obstruction 0.6 0.3–1.1 0.101 0.3 0.1–0.7 0.005
Cirrhosis /liver disease 1.0 0.8–1.2 0.719 0.5 0.3–0.6 <0.001
Genitourinary system
Renal diseases/dialysis 1.1 0.8–1.5 0.522 0.6 0.3–1.2 0.153
Signs and symptoms
Ill-defined/ unknown 1.3 0.4–4.4 0.710 0.6 0.4–1.0 0.038
Injury and poisoning
Intentional self-harm 1.5 1.0–2.1 0.035 1.3 0.8–1.9 0.285
Accidental falls 0.8 0.5–1.5 0.560 0.7 0.4–1.1 0.135
Accidental poisoning1 0.9 0.7–1.3 0.599 0.8 0.5–1.3 0.372
Choking on food/solids2 3.7 1.6–8.6 0.003 NE
†Hazard ratios adjusted for age, sex, accessibility, relative disadvantage, indigenous status, partner status, country of birth and number of comorbid conditions.
¥See Table 2 for the number of decedents included in each cause of death subset regression model. The clustered sandwich estimator was used to account for clustering
of events and strata weights applied. Proportional hazards assumed.
1Includes poisoning by analgesics, antipyretics, antirheumatics, narcotics, psychodysleptics, antiepileptic, sedative-hypnotic, anti-parkinsonism or psychotropic drugs.
2 Inhalation and ingestion of food causing obstruction of respiratory tract. NE, not estimable due to small numbers with this cause of death.
https://doi.org/10.1371/journal.pone.0208220.t005
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choking on food/solids or intentional self-harm mentioned anywhere on their death certifi-
cate, decedents with schizophrenia tended towards higher rates of ED use in the last year of life
compared to decedents from the matched cohort. Amongst decedents who died from inten-
tional self-harm, 40.1% (n = 107) of ED presentations for people with schizophrenia were
because of social/behavioural or drug/alcohol problems, compared to 26.9% (n = 806) of ED
presentations for people without schizophrenia (p<0.001). Of all decedents who had ischaemic
heart disease or respiratory disease recorded as a morbid event on their death certificate, there
was no difference in the rates of ED use in the last year of life between those with schizophrenia
and those in the matched cohort, except perhaps a trend of lower ED use in decedents with
schizophrenia who died with influenza or pneumonia.
Hospital admissions
In general, decedents with a history of schizophrenia demonstrated less frequent hospital
admissions compared to matched comparison decedents, but they tended towards staying in
hospital longer once admitted (Table 4). Relatively fewer females but not males with schizo-
phrenia were admitted to hospital at least once compared to their gender matched cohort.
Hospital admissions by decedents with schizophrenia were more often for psychogeriatric
care, maintenance care and rehabilitation but less often for acute care or palliative care. Of
decedents with schizophrenia who were admitted to hospital, more were emergency admis-
sions, involved more days of psychiatric care, involved more intensive care (males only) or
ventilator support (females only).
The average unadjusted rate of hospital admissions for the schizophrenia cohort was consis-
tently lower than the matched comparison cohort over the last year of life (Fig 2A) a trend that
was consistent for both males and females. After adjusting for confounders, the rates of hospi-
tal admission over the last year of life for decedents with schizophrenia remained consistently
lower for both females and males than their gender matched cohort (Average HR 0.53; 95%CI
0.44–0.65).
Rates of hospital admission generally showed a lower trend in decedents with schizophrenia
for almost all causes of death, although limited statistical power was present in less common
causes of death. Overall, decedents with schizophrenia who died from cancer had 40% lower
rates of hospital admission in the last year of life compared to the matched cohort who also
died from cancer, except for breast cancer where admission rates were similar. Lower rates of
hospital admissions in the last year of life were observed for decedents with schizophrenia who
had infections (influenza, pneumonia or bacterial sepsis), diseases of the circulatory system
(ischaemic heart disease, heart failure and cerebrovascular disease), liver disease and pneumo-
nitis recorded on their death certificate compared to decedents in the matched cohort with the
same conditions. There were no causes of death where rates of hospital admission by decedents
with schizophrenia was higher than the matched cohort, except a non-significant increase for
those who died from intentional self-harm.
Community-based care in the last year of life
Just under 7% of all decedents with schizophrenia accessed community-based specialist pallia-
tive care in the last year of life compared to 16% of decedents in the matched cohort (Table 6).
When restricted to decedents who died from conditions considered amenable to palliative
care around 12% of decedents with schizophrenia and 25% of the matched cohort received
community-based specialist palliative care. Decedents with cancer accessed the greatest pro-
portion of community-based specialist palliative care in both cohorts.
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The relative rate of ED presentation and hospital admissions during periods of time of
receiving community-based specialist palliative care compared to periods of time not receiving
this care were investigated on the subset of decedents with conditions amenable to palliative
care (Table 7). Amongst decedents with schizophrenia, days enrolled in community-based
specialist palliative care was associated with no change in rate of ED presentations and a 50%
increase in rate of hospital admissions. Amongst decedents in the matched cohort, periods of
time enrolled in the service was associated with reduced rates of ED admissions but no differ-
ence in rate of hospital admissions.
Around 42% of decedents in both the schizophrenia cohort and matched cohort were regis-
tered as clients of community-based (non-palliative) care services in last year of life. Decedents
with schizophrenia were more likely to have received centre-based day care, counselling for
both client and carer, social support, personal care and client management services compared
to the matched cohort.
Discussion
We report that health service use in the last of life for people with schizophrenia living in West-
ern Australia is very different to that experienced by people without schizophrenia. People
with schizophrenia died from different causes of death, had unique patterns of ED use, were
half as likely to enrol in community-based specialist palliative care and were half as likely to be
admitted to hospital in the last year of life compared to people without schizophrenia who had
a similar sociodemographic profile.
Fig 2. The average yearly (hazard) rate of hospital admissions per decedent over the last year of life for the
schizophrenia and matched cohorts and stratified by sex estimated from A) an unadjusted kernel-weighted
estimator of the hazard and B) a flexible parametric proportional hazards model adjusted for age at death,
comorbidity, socioeconomic status, accessibility index, sex, partner status, indigenous status and country of birth.
Hazard rates and 95%CI in B are those predicted for Australian born non-Indigenous decedents living in a
metropolitan area of average disadvantage without a partner, aged 50 years or older at death and with three comorbid
conditions.
https://doi.org/10.1371/journal.pone.0208220.g002
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Causes of death
The leading causes of death for people with schizophrenia were cancers, diseases of the circula-
tory system, intentional self-harm and accidental poisoning (drug overdoses) compared to an
age-matched cohort, patterns similar to that reported in Canada [36], United States [4] and
Sweden [37]. Deaths from epilepsy were overrepresented in decedents with schizophrenia.
Temporal lobe epilepsy has long been associated with a schizophrenia-like psychosis although
Table 6. Summary of community-based non-palliative and specialist palliative care accessed in the last year of life
by the schizophrenia and matched cohorts.
Community-based care
accessed in the last year of life
Schizophrenia
Cohort
N = 1194
Matched
Cohort†
N = 39265
N % N % P-value
Specialist palliative care
Registered decedents 78 6.5 6217 15.8 <0.001
Total hours care per decedent (mean, se) 13.2 2.3 23.3 0.8 <0.001
No. (%) decedents with COD amenable
to palliative care who received SPC‡ 74 11.9 5831 24.7 <0.001
By specific causes of death
Cancers 60 27.5 5324 40.4 <0.001
Heart failure 8 5.8 286 7.5 0.472
Renal disease 5 5.6 415 11.1 0.122
Chronic lower respiratory disease 10 7.3 397 12.8 0.066
Dementias <5 2.6 209 5.9 0.111
Cirrhosis and liver failure <5 9.1 264 13.0 0.494
Parkinson’s disease <5 3.9 22 5.3 0.781
Non-palliative care
Registered decedents 528 44.2 16331 41.6 0.075
Services accessed
Allied health care (centre) 7 0.6 236 0.6 0.951
Allied health care (home) 77 6.5 2564 6.5 0.913
Assessment 468 39.2 14567 37.1 0.148
Centre based day care 132 11.1 3243 8.3 <0.001
Client care coordination 333 27.9 9456 24.1 0.003
Counselling (client) 162 13.6 4363 11.1 0.009
Counselling (carer) 111 9.3 2576 6.7 <0.001
Domestic assistance 245 20.5 8148 20.8 0.847
Home maintenance 115 9.6 3678 9.4 0.761
Nursing care (home) 175 14.7 5499 14.0 0.530
Nursing care (centre) 12 1.0 360 0.9 0.761
Personal care 159 13.3 4440 11.3 0.034
Respite care 29 2.4 1115 2.8 0.403
Social support 200 16.8 4295 10.9 <0.001
† Coarsened exact matching strata weights applied and p-values corrected to account for study design.
‡ Causes of death amenable to palliative care were defined as occurring anywhere on the death certificate. Decedents
could have had more than one causes of death amenable to palliative care which is why the total exceeds the number
of decedents registered for the service. Numbers less than five are suppressed. SPC, specialist palliative care; COD,
cause of death; se, standard error.
https://doi.org/10.1371/journal.pone.0208220.t006
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understanding of the neuropathological and temporal mechanisms remain unclear. [38] Just
over 2% of all decedents with schizophrenia had Parkinson’s disease recorded as the underly-
ing or a contributory cause of death. Coexistence of schizophrenia with Parkinson’s disease is
generally considered a rare condition with the hyperactive dopamine transmission observed in
schizophrenia considered oppositional to the dopaminergic deficiency underlying Parkinson’s
disease. [39] It is possible that drug-induced Parkinsonism, the result of anti-psychotic medi-
cation, was misclassified as Parkinson’s disease in most cases in our study.
The over representation of death from pneumonitis due to solids/liquids and choking in
decedents with schizophrenia are not unexpected as disorders of swallowing are common and
result from both the illness and the medication used to treat psychotic disorders [40]. An
increased number of deaths with intestinal obstruction were observed in decedents with
schizophrenia, possibly associated with gastrointestinal hypomotility induced by some antipsy-
chotic agents, such as clozapine. [41]
ED use in last year of life
The association of schizophrenia with rate of ED use in the last year of life was complex and
varied with sex and comorbidity. Within the subset of decedents without a history of
comorbidity, males with schizophrenia were the highest users of ED. The greater proportion
of ED presentations involving police or corrective services and symptoms related to alcohol
and drug abuse and behavioural problems in males with schizophrenia reflects common
psychiatric comorbidities in this group. Decedents with schizophrenia who died of inten-
tional self-harm presented to ED 50% more often in the last year of life than decedents with-
out schizophrenia who also died from self-harm. More ED presentations for social/
behavioural and drug and alcohol problems in people with schizophrenia who died from
suicide suggests less stable schizophrenia and consequences of psychosis. However, as dece-
dents with schizophrenia who died with cancer also had higher rates of ED presentation
compared to the matched cohort, reasons for increased ED use are likely multifactorial and
include patient, provider and system processes. People with schizophrenia and cancer may
find it difficult to communicate medical history and health care providers may be more
likely to attribute medical symptoms to the schizophrenia [9], potentially leading to repeat
ED presentations.
Table 7. Association of community-based specialist palliative care with rates of ED presentations and hospital admissions for the schizophrenia and matched
cohorts amongst the subset of decedents who died from conditions amenable to palliative care (n = 18,946).
Decedents with cause of death
amenable to palliative care¥
ED presentations† Hospital admission†
HR 95%CI p HR 95%CI p
Receiving SPC versus no SPC care within
Schizophrenia cohort (n = 425) 1.2 0.8–1.7 0.372 1.5 1.1–2.1 0.011
Matched cohort (n = 18521) 0.8 0.7–0.9 <0.001 1.0 0.9–1.1 0.649
Schizophrenia vs matched cohort within
Days enrolled in SPC care 1.6 1.2–2.4 0.007 0.8 0.6–1.0 0.041
Days not enrolled in SPC care 1.1 1.0–1.4 0.101 0.5 0.4–0.7 <0.001
†Relative hazard (rates) adjusted for age, sex, accessibility index, relative disadvantage, indigenous status, partner status, country of birth and number of Elixhauser
comorbid conditions.
¥Cancers, organ failures, dementia, Parkinson’s disease and chronic obstructive pulmonary disease. The clustered sandwich estimator was used to account for intra-
decedent clustering of events and strata weights applied. SPC, community-based specialist palliative care; COD, cause of death; ED, emergency department; HR, hazard
rate.
https://doi.org/10.1371/journal.pone.0208220.t007
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In the subset of decedents who were dying with conditions amenable to palliative care, we
observed that periods of time receiving community-based specialist palliative care was associ-
ated with reduced ED presentations for the matched cohort in the last year of life, as reported
previously in Western Australia. [15] However, this was not the case in decedents with schizo-
phrenia where no change in the rates of ED presentation during periods receiving and not
receiving community-based specialist palliative care were observed. We speculate that contact
with a specialist palliative care change was likely to have influenced the motivators of ED pre-
sentation in people with schizophrenia, however our data lacked the clinical detail and statisti-
cal power to identify if any subtle changes in the reasons for ED presentations during times
with and without palliative care had occurred.
Hospital use in the last year of life
Overall the rate of hospital admission in the last year of life was 50% reduced in decedents with
schizophrenia, larger than the 27% reduction in rate of hospital separations by people with schizo-
phrenia in the last six months of life reported in a Canadian study. [12] This difference could
partly be explained by methodology as we excluded person-time at risk while hospitalised.
Reduced rates of hospital admission for people with schizophrenia were evident across
most causes of death with the strongest evidence observed for infections, cancers, most circula-
tory system diseases, dementias, depression, alcohol abuse and liver disease. The only causes of
death where rates of hospital admission were similar between the cohorts were for breast can-
cer and intentional self-harm. While the average length of hospital stay was longer and
involved more days of psychiatric care for decedents with schizophrenia, reduced rates of hos-
pitalisation likely represent the same complex interaction of patient, individual clinician and
healthcare system factors that contribute to disparate outcomes in other marginalised groups.
In the subset of decedents with schizophrenia who also had conditions amenable to pallia-
tive care, being enrolled in community-based specialist palliative care was associated with a
50% increase in rates of hospital admission. This finding suggests that receiving home-based
specialist palliative care is reducing barriers to accessing hospital care. However, our data were
insufficiently detailed to determine whether this increase reflected appropriate hospitalizations
or instead reflected reduced access to appropriate care elsewhere in the community. Further
work is required to address this issue.
Access to community-based care
We found evidence that people with schizophrenia who are dying with conditions amenable to
palliative care were half as likely to receive specialist palliative care in the home compared to
the matched cohort. This is similar to findings from New Zealand [42] and Canada. [12] Yet,
we found that decedents with schizophrenia were just as likely to have accessed non-palliative
community-based services in the last year of life as decedents without schizophrenia. Studies
from countries with universal health care like Australia have also reported regular and
increased access to GP services by people with schizophrenia. [12, 43] This suggests the barri-
ers inhibiting receipt of palliative care for people with schizophrenia are at least partly health
system driven rather than patient driven. Considering the vulnerability of people with schizo-
phrenia to poorer general health outcomes and lower life expectancy, efforts to remedy this are
essential.
Study strengths and limitations
Strengths of this study were the population based source of participants and record linkage
across multiple different datasets. Limitations of the study included lack of clinical information
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and certainty related to schizophrenia diagnosis, particularly when coded in emergency
department data or as a comorbid condition in hospital records. Our cohort of decedents with
schizophrenia were selected from administrative records dating back to 1970 so misclassifica-
tion of older decedents with schizophrenia who only had hospital records prior to this time
was possible. It is also possible that comorbidity was either reported less frequently on medical
records or was underdiagnosed for people with schizophrenia possibly leading to some differ-
ential bias. Lack of accurate date of service data for the community-based non-palliative care
limited interpretation. Our methodological approach involved multiple regression models,
thus interpretation of findings raises the issue of multiple comparisons. We did not make sta-
tistical adjustment to account for multiple testing in this study based on the view that readers
will take the design of the study, the associated effect sizes, support from other published stud-
ies and our conservative interpretation into account. We also note that for less frequent failure
events and small cause of death categories, the statistical power was only sufficient to detect
very large differences between the two cohorts and that false positive findings were also
possible.
In the last year of life, people with schizophrenia were less likely to be admitted to hospital,
more likely to attend ED if male, less likely to access community-based speciality palliative
care and had a different comorbidity and cause of death burden compared to matched dece-
dents with a similar sociodemographic profile. Community-based specialist palliative care was
associated with increased rates of hospital admission in decedents with schizophrenia. Our
findings suggest that accessing community-based specialised palliative care can provide an
alternative path to hospital care for persons with schizophrenia dying from conditions amena-
ble to palliative care during the last year of life.
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